Navigation Links
Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
Date:12/14/2007

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert Conley, M.D., will join Lilly in January, 2008, as a Distinguished Lilly Scholar focusing on schizophrenia and other psychotic illnesses.

"We are absolutely delighted to have Dr. Conley join our team here at Lilly," said Jack Harris, M.D., vice president, U.S. Medical Division. "Rob is a well-known thought leader, clinician and scientist who brings important experience to Lilly as we continue to realize our vision of serving the patient. His experience will allow him to play a key scientific leadership role in our relationships with the U.S. physician community as well as the broader clinical and scientific communities."

Conley joins Lilly from the University of Maryland in Baltimore, where he is professor of psychiatry and pharmacy science. His work there focused on developing better treatments for patients with schizophrenia and other psychotic illnesses. With his colleagues at the Maryland Psychiatric Research Center and the National Institute on Drug Abuse, he also helped improve treatment for patients with poorly responsive schizophrenia through increased understanding of the most effective and safest ways to use antipsychotics.

After receiving his bachelor's degree from the John Hopkins University, Conley earned his medical degree from the University of Maryland in Baltimore. He did post-graduate work at the Western Psychiatric Institute & Clinic at the University of Pittsburgh before joining the faculty at the University of Maryland in Baltimore. He is an accomplished author and serves on numerous national peer-review boards.

"I am very pleased that Rob has decided to join Lilly," said Alan Breier, M.D., vice president and Lilly's chief medical officer. "He is an internationally recognized leader in schizophrenia research and will bring great technical depth and disease state knowledge to our company. Our commitment to neuroscience is quite strong, and the addition of Rob only strengthens our expertise in this area."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
2. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
3. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
6. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
7. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
8. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
9. Amarin Signs Agreement to Acquire Ester Neurosciences
10. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
11. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... 2017  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Annual Biocom Global Life Science Partnering Conference.  The presentation ... at the Torrey Pines Lodge, in San Diego.  ... Biocom who have chosen our company, amongst numerous others, ... investors, and clinical researchers," said Mr. Chen. "In contrast ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):